Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781807 | 0.96 | — | — | |
| Iodide SCHEMBL9421128 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL28705517 | 0.93 | — | — | |
| Water SCHEMBL28351618 | 0.93 | — | — | |
| SCHEMBL430642 | 0.80 | SLC22A16 (0.44) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| Formic Acid SCHEMBL3681464 | 0.80 | SLC22A16 (0.44) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| Prolonium SCHEMBL1649967 | 0.77 | MAPT (0.52) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| Prolonium SCHEMBL11723705 | 0.74 | MAPT (0.50) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| Prolonium SCHEMBL2889745 | 0.74 | MAPT (0.57) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| Prolonium SCHEMBL5705670 | 0.74 | MAPT (0.50) | MAPTSLC22A16TSHRCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017463-A1 | Salt Form of Estrogen Receptor Downregulator, Crystalline Form Thereof, and Preparation Method Therefor | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3889136-A1 | SALT FORM OF ESTROGEN RECEPTOR DOWNREGULATOR, CRYSTALLINE FORM THEREOF, AND PREPARATION METHOD THEREFOR | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017463-A1 | Salt Form of Estrogen Receptor Downregulator, Crystalline Form Thereof, and Preparation Method Therefor | NR5A1, ESRRA, SHBG | MAPT 2763/4885SLC22A16 405/4885TSHR 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.